drugset

drugset / Trial / NCT00241475

Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy

NCT00241475 ↗

Phase 2 Completed 30 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating PSA response rate at study closure

Timeline

Start: 2003-12
Primary completion: —
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefitinib	Small molecule	—	—

Indications